American College of Clinical Pharmacy
      Search      Cart

BCOP Clinical Sessions -- Updates on New Drugs and the Management of Nausea and Vomiting

Monday, October 09, 2017 from 8:30 AM to 10:30 AM MST at Phoenix Convention Center North Building Street Level: Meeting Room 121

Available for 2.00 hours of CPE credit
Activity Number: 0217-9999-17-162-L01-P
Activity Type: An Application-Based Activity

The BCOP clinical sessions are part of the professional development program for the recertification of board-certified oncology pharmacists, approved by the Board of Pharmacy Specialties and cosponsored by ACCP and the American Society of Health-System Pharmacists (ASHP). During the oncology pharmacy specialty sessions, instructions for accessing the BCOP recertification posttests will be provided (two posttests - one for each session). Posttest will be available on or around November 30.
New Drugs Update
8:30 AM to 9:30 AM

  • Amanda N. Seddon, Pharm.D., BCPS, BCOPFaculty: Amanda N. Seddon, Pharm.D., BCPS, BCOP
    Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy, Rush University Medical Center, Chicago, Illinois

Learning Objectives
1. Evaluate the clinical benefit of olaratumab in soft tissue sarcomas.
2. Examine the relationship between BRCA mutations and PARP inhibitors and distinguish the therapeutic role of PARP inhibition in ovarian cancer.
3. Examine the role of CDK 3/4 inhibition in breast cancer and the clinical benefit of ribociclib.
4. Recommend a monitoring plan and dose adjustment to manage ribociclib toxicities.
5. Compare the mechanism of action of PD-1 and PD-L1 inhibitors.
6. Assess the clinical benefit and place in therapy for durvalumab and avelumab.
7. Discuss the prognostic significance of FLT3 mutated AML and explain the clinical benefit seen with midostaurin in the RATIFY trial.
Updates on the Management of Nausea and Vomiting
9:30 AM

  • Mary  Golf, Pharm.D.Faculty: Mary Golf, Pharm.D.
    Pharmacy Manager, Hematology/Oncology; PGY2 Oncology Residency Program Director, Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois

Learning Objectives
1. Summarize the key elements of chemotherapy-induced nausea and vomiting.
2. Assess the current, published guidelines for chemotherapy-induced nausea and vomiting.
3. Identify and recommend therapeutic options for the management of chemotherapy-induced nausea and vomiting.